287 related articles for article (PubMed ID: 12730088)
1. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Tuleja E; Mejza F; Cmiel A; Szczeklik A
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
[TBL] [Abstract][Full Text] [Related]
2. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
4. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time.
Blaicher AM; Landsteiner HT; Zwerina J; Leitgeb U; Volf I; Hoerauf K
Anaesthesia; 2004 Nov; 59(11):1100-3. PubMed ID: 15479319
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
6. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
7. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
[TBL] [Abstract][Full Text] [Related]
9. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
10. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
11. COX-1 and COX-2 inhibitors.
Hawkey CJ
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation.
Verma S; Raj SR; Shewchuk L; Mather KJ; Anderson TJ
Circulation; 2001 Dec; 104(24):2879-82. PubMed ID: 11739299
[TBL] [Abstract][Full Text] [Related]
13. Biomedicine. Back to an aspirin a day?
Vane JR
Science; 2002 Apr; 296(5567):474-5. PubMed ID: 11964462
[No Abstract] [Full Text] [Related]
14. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis.
Souza MH; de Lima OM; Zamuner SR; Fiorucci S; Wallace JL
Am J Physiol Gastrointest Liver Physiol; 2003 Jul; 285(1):G54-61. PubMed ID: 12637254
[TBL] [Abstract][Full Text] [Related]
15. Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
Weber AA; Heim HK; Schumacher M; Schrör K; Hohlfeld T
Platelets; 2007 Aug; 18(5):379-85. PubMed ID: 17654308
[TBL] [Abstract][Full Text] [Related]
16. COX-2 selective NSAID decreases bone ingrowth in vivo.
Goodman S; Ma T; Trindade M; Ikenoue T; Matsuura I; Wong N; Fox N; Genovese M; Regula D; Smith RL
J Orthop Res; 2002 Nov; 20(6):1164-9. PubMed ID: 12472224
[TBL] [Abstract][Full Text] [Related]
17. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
18. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
19. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
20. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Whelton A
J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
